Manmeet S Ahluwalia Selected Research

ErbB Receptors (EGF Receptor)

3/2024	Executive Summary of the American Radium Society Appropriate Use Criteria for Brain Metastases in EGFR-mutated and ALK-fusion Non-Small Cell Lung Cancer.
12/2023	Management of Brain Metastases: A Review of Novel Therapies.
1/2022	Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors.
11/2021	Systematic review and meta-analysis of lung cancer brain metastasis and primary tumor receptor expression discordance.
1/2020	Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.
1/2019	Current Treatment Options for Breast Cancer Brain Metastases.
1/2019	Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.
10/2018	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.
4/2017	Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
4/2013	NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Manmeet S Ahluwalia Research Topics

Disease

70	Brain Neoplasms (Brain Tumor) 03/2024 - 11/2013
67	Neoplasms (Cancer) 04/2024 - 01/2010
37	Glioblastoma (Glioblastoma Multiforme) 10/2023 - 05/2006
26	Neoplasm Metastasis (Metastasis) 03/2024 - 04/2014
21	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2024 - 05/2010
21	Glioma (Gliomas) 02/2023 - 01/2010
15	Breast Neoplasms (Breast Cancer) 12/2023 - 09/2005
14	Melanoma (Melanoma, Malignant) 03/2024 - 01/2016
13	Lung Neoplasms (Lung Cancer) 03/2024 - 01/2016
10	Necrosis 01/2023 - 11/2013
5	Renal Cell Carcinoma (Grawitz Tumor) 07/2023 - 12/2017
3	Lymphoma (Lymphomas) 03/2020 - 08/2010
3	Disease Progression 01/2020 - 05/2010
3	Edema (Dropsy) 01/2017 - 06/2013
2	Oligodendroglioma 01/2022 - 03/2015
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 01/2019
2	Thrombocytopenia (Thrombopenia) 01/2019 - 01/2018
2	Exanthema (Rash) 01/2019 - 05/2010
2	Residual Neoplasm 08/2018 - 09/2010
2	Hemorrhage 04/2018 - 06/2016
2	Adenocarcinoma 01/2018 - 07/2017
2	Kidney Neoplasms (Kidney Cancer) 01/2018 - 01/2016
2	Neurologic Manifestations (Neurological Manifestations) 08/2017 - 12/2016
1	Spinal Diseases (Disease, Spinal) 01/2024
1	Spinal Cord Compression 01/2024
1	Spinal Fractures 01/2024
1	Congenital Abnormalities (Deformity) 01/2024
1	Microsatellite Instability 01/2024
1	Turcot syndrome 01/2024
1	Sarcoma (Soft Tissue Sarcoma) 12/2023

Drug/Important Bio-Agent (IBA)

16	Immune Checkpoint InhibitorsIBA 10/2023 - 11/2015
15	Temozolomide (Temodar)FDA LinkGeneric 10/2023 - 05/2010
11	ErbB Receptors (EGF Receptor)IBA 03/2024 - 05/2010
10	Tyrosine Kinase InhibitorsIBA 03/2024 - 02/2010
10	Bevacizumab (Avastin)FDA Link 09/2023 - 01/2013
6	Biomarkers (Surrogate Marker)IBA 04/2024 - 01/2019
6	SteroidsIBA 01/2022 - 06/2013
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2017 - 10/2012
5	Anaplastic Lymphoma KinaseIBA 12/2023 - 01/2016
3	human ERBB2 proteinIBA 12/2023 - 01/2019
3	SurvivinIBA 01/2023 - 08/2010
3	Peptides (Polypeptides)IBA 01/2020 - 08/2010
3	Monoclonal AntibodiesIBA 11/2017 - 01/2013
2	RadiumIBA 03/2024 - 01/2022
2	Proteins (Proteins, Gene)FDA Link 03/2024 - 11/2018
2	tyrosine receptor (receptor, tyrosine)IBA 01/2024 - 12/2023
2	Phosphotransferases (Kinase)IBA 01/2024 - 12/2023
2	CytokinesIBA 10/2023 - 01/2018
2	MethyltransferasesIBA 09/2023 - 08/2018
2	osimertinibIBA 04/2023 - 10/2018
2	Messenger RNA (mRNA)IBA 01/2023 - 11/2018
2	Protein Subunit VaccinesIBA 01/2023 - 11/2016
2	B7-H1 AntigenIBA 01/2022 - 01/2021
2	Lomustine (CCNU)FDA Link 01/2022 - 02/2011
2	Adrenal Cortex Hormones (Corticosteroids)IBA 07/2021 - 01/2017
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021 - 01/2019
2	EnzymesIBA 01/2021 - 01/2019
2	Lapatinib (GW572016)FDA Link 01/2019 - 01/2019
2	Trastuzumab (Herceptin)FDA Link 01/2019 - 10/2005
2	LigandsIBA 01/2019 - 08/2010
2	TOR Serine-Threonine KinasesIBA 01/2018 - 09/2015
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 09/2017 - 01/2015
2	cediranib (AZD2171)IBA 10/2015 - 02/2011
2	Sunitinib (Sutent)FDA Link 09/2015 - 02/2011
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 04/2013 - 05/2010
1	Transcription Factors (Transcription Factor)IBA 03/2024
1	Galectin 3 (LGALS3)IBA 03/2024
1	Interleukin-8 (Interleukin 8)IBA 03/2024
1	Matrix Metalloproteinase 3 (Stromelysin 1)IBA 03/2024
1	ElementsIBA 01/2024
1	Opioid Analgesics (Opioids)IBA 01/2024
1	Ado-Trastuzumab EmtansineIBA 12/2023
1	encorafenibIBA 12/2023
1	VemurafenibIBA 12/2023
1	trastuzumab deruxtecanIBA 12/2023
1	brigatinibIBA 12/2023
1	adagrasibIBA 12/2023
1	sotorasibIBA 12/2023
1	larotrectinibIBA 12/2023
1	selpercatinibIBA 12/2023
1	pralsetinibIBA 12/2023
1	Immunoconjugates (Immunoconjugate)IBA 12/2023
1	ensartinibIBA 12/2023
1	HM781-36BIBA 12/2023
1	entrectinibIBA 12/2023
1	Macrophage Migration-Inhibitory FactorsIBA 10/2023
1	LactoferrinIBA 10/2023
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 09/2023

Therapy/Procedure

68	Therapeutics 01/2024 - 07/2004
44	Radiotherapy 03/2024 - 05/2006
18	Drug Therapy (Chemotherapy) 01/2023 - 10/2011
18	Immunotherapy 10/2022 - 01/2013
3	Re-Irradiation 01/2023 - 11/2017
3	Combined Modality Therapy 01/2022 - 11/2013
2	Chemoradiotherapy 10/2023 - 01/2023
2	Aftercare (After-Treatment) 01/2023 - 01/2016
2	Precision Medicine 01/2019 - 11/2018
2	Lasers (Laser) 01/2014 - 06/2013
2	Molecular Targeted Therapy 01/2013 - 09/2012
1	Adjuvant Chemoradiotherapy 10/2023